Antibiotic Resistant Organism (ARO) Risk Factor-Based Screening Guidance for All Health Care Settings



Screening Checklists

Published: June 2024

Introduction

Risk factor-based screening identifies clients / patients / residents at increased risk of having an antibiotic resistant organism (ARO).

When risk factors are identified, the client / patient / resident is tested for AROs from specific body sites that are known to become colonized by specific organisms. The goal of ARO screening is to identify all clients / patients / residents who are colonized or infected with an ARO as early as possible, in order to implement infection prevention and control measures to reduce the risk of transmission to others.

This resource is intended for use by all health care settings, including hospitals, long-term care and retirement homes, and ambulatory care settings.

Additional Resources:

- Management of a Single New Case of Candida Auris (C. auris)
- Management of a Single New Case of MRSA
- Management of a Single New Case of VRE
- Management of a Single New Case of CPE

Contents

Methicillin-Resistant <i>Staphylococcus aureus</i> (MRSA), Vancomycin Resistant Enterococci (VRE) and Carbapenemase-Producing <i>Enterobacteriaceae</i> (CPE) Risk Factor-Based Screening Guidance	2
Follow-up Actions for a Positive MRSA, VRE or CPE Screen	
Candida auris Risk Factor-Based Guidance	
Follow-up Actions for a Positive <i>C. auris</i> Screen	3
References	4

Client / Patient / Resident Information			
First name:	Last name:		
Date of birth (yyyy-mm-dd):			
Assessor Information			
First name:	Last name:		
Position:	Date (yyyy-mm-dd):		
A. Methicillin-Resistant Staphylococcu Enterococci (VRE) and Carbapenemas Based Screening Guidance	• • • • • • • • • • • • • • • • • • • •		actor-
Has the patient / resident spent time in a health (including the United States) within the previou		Yes	No
 If yes, initiate Contact Precautions in a private and dedicate all equipment and supplies as al 			
Has the patient / resident been transferred from ongoing outbreak of MRSA, VRE, or CPE?	n a unit in a health care facility with an	Yes	No
 If yes, initiate Contact Precautions in a private and dedicate all equipment and supplies as al 			
Does the patient / resident have a prior history MRSA, VRE, or CPE, or is the patient / resider MRSA, VRE, or CPE?		Yes	No
 If yes, initiate Contact Precautions in a private and dedicate all equipment and supplies as al 			
Is the patient / resident chart flagged with a his MRSA, VRE, or CPE?	story of exposure to another case of	Yes	No
 If yes, and the exposure was to a case of CPE private room with dedicated toileting facilities, as able. Contact Precautions for MRSA or VR depending on your local risk assessment. 	and dedicate all equipment and supplies		
Has the patient / resident been admitted, or sp facility (including this one) within the previous		Yes	No
Has the patient / resident been directly transfer (e.g., hospital-to-hospital, long-term care home	•	Yes	No
Does the patient / resident belong to a high-ris Prevention and Control or Public Health (e.g., a areas, or resides in an area with high rates of o	admission to ICU, travel to high-risk	Yes	No

Follow-up Actions for a Positive MRSA, VRE or CPE Screen

See indications for initiating Additional Precautions within **Section A**. If the patient or resident answers 'yes' to any of the previous questions, or is unable then test according to the following guidance:

Test for MRSA, VRE and CPE.					
Sites to swab for MRSA include:	Sites to swab / specimens to collect for VRE include:	Sites to swab / specimens to collect for CPE include:			
 Anterior nares AND Perineal / perianal (preferred) or groin area AND Skin lesions, wounds, incisions, ulcers and exit sites of indwelling devices AND For newborns only, include umbilicus 	Stool (preferred) OR Rectal swab If a patient / resident has a colostomy, the VRE specimen may be taken from the colostomy output	 Stool (preferred) OR rectal swab AND, as indicated: Urine Open wounds In ICU: Sputum, endotracheal tube, exit sites 			

B. Candida auris Risk Factor-Based Guidance

Has the patient / resident been admitted to a health care facility outside of Canada (including the United States) within the previous 12 months?	Yes	No
Has the patient / resident been transferred from a Canadian health care facility with an ongoing outbreak or transmission of <i>C. auris</i> ?	Yes	No
Does the patient / resident have a prior history of colonization or infection with <i>C. auris</i> ?	Yes	No
Is the patient / resident chart flagged with a history of <i>C. auris</i> , or <i>C. auris</i> exposure?	Yes	No

Follow-up Actions for a Positive C. auris Screen

If the patient or resident answers 'yes' to any of the questions in **Section B**, or is unable to answer any of the screening questions in **Section A**:

Initiate Contact Precautions in a private room with dedicated toileting facilities, and dedicate all equipment and supplies as able.

Test for C. auris

Sites to swab for Candida auris include:

- · Combined bilateral axilla and groin
- Nares
 - Previously colonized, or clinically relevant sites (e.g., wounds, exit sites, external ear canal) may also be indicated

References

- Public Health Agency of Canada. Candida auris interim recommendations for infection prevention and control [Internet]. Ottawa, ON: Government of Canada; 2022 [cited 2023 Jul 26]. Available from: https://www.canada.ca/en/public-health/services/infectious-diseases/nosocomial-occupational-infections/notice-candida-auris-interim-recommendations-infection-prevention-control.html
- 2. Ontario Agency for Health Protection and Promotion (Public Health Ontario). Interim guide for infection prevention and control of Candida auris [Internet]. Toronto, ON: Queen's Printer for Ontario; 2019 [cited 2023 Jul 26]. Available from: https://www.publichealthontario.ca/-/media/Documents/C/2023/candida-auris.pdf
- 3. Ontario Agency for Health Protection and Promotion, Provincial Infectious Diseases Advisory Committee. Annex A Screening, testing and surveillance for antibiotic-resistant organisms (AROs). Annexed to: Routine practices and additional precautions in all health care settings. Toronto, ON: Queen's Printer for Ontario; 2013. Available from: https://www.publichealthontario.ca/-/media/documents/a/2013/aros-screening-testing-surveillance.pdf

Citation

Ontario Agency for Health Protection and Promotion (Public Health Ontario). Antibiotic Resistant Organism (ARO) risk factor-based screening guidance. Toronto, ON: King's Printer for Ontario; 2024.

Disclaimer:

This document was developed by Public Health Ontario (PHO). PHO provides scientific and technical advice to Ontario's government, public health organizations and health care providers. PHO's work is guided by the current best available evidence at the time of publication. The application and use of this document is the responsibility of the user. PHO assumes no liability resulting from any such application or use. This document may be reproduced without permission for non-commercial purposes only and provided that appropriate credit is given to PHO. No changes and/or modifications may be made to this document without express written permission from PHO.

Public Health Ontario:

Public Health Ontario is an agency of the Government of Ontario dedicated to protecting and promoting the health of all Ontarians and reducing inequities in health. Public Health Ontario links public health practitioners, front-line health workers and researchers to the best scientific intelligence and knowledge from around the world.

For more information, visit publichealthontario.ca

© King's Printer for Ontario, 2024

